Acoramidis

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 93 publications

Acoramidis for ATTR cardiomyopathy: value, access, and the duty to treat.

Acoramidis for ATTR cardiomyopathy: value, access, and the duty to treat.

Journal: European heart journal. Quality of care & clinical outcomes
Published: May 26, 2026

Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy With and Without Atrial Fibrillation: Results From ATTRibute-CM.

Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy With and Without Atrial Fibrillation: Results From ATTRibute-CM.

Journal: Journal of cardiac failure
Published: May 08, 2026

Therapy of amyloidosis: stabilizers and silencers.

Therapy of amyloidosis: stabilizers and silencers.

Journal: European heart journal supplements : journal of the European Society of Cardiology
Published: May 08, 2026

The Promise and Pitfalls of TTR Stabilization Assays in ATTR-CM.

The Promise and Pitfalls of TTR Stabilization Assays in ATTR-CM.

Journal: JACC. CardioOncology
Published: April 08, 2026

ATTR-CM: What do we know about blood levels of the TTR protein? A discussion with experts.

ATTR-CM: What do we know about blood levels of the TTR protein? A discussion with experts.

Journal: Therapeutic advances in cardiovascular disease
Published: April 02, 2026

Early Five-Month Response to Acoramidis in ATTR-CM Assessed by SUVmax Using 99mTc-HMDP SPECT/CT.

Early Five-Month Response to Acoramidis in ATTR-CM Assessed by SUVmax Using 99mTc-HMDP SPECT/CT.

Journal: QJM : monthly journal of the Association of Physicians
Published: March 31, 2026

Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial.

Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial.

Journal: JAMA cardiology
Published: March 30, 2026

Outpatient worsening heart failure in transthyretin amyloid cardiomyopathy: Findings from ATTRibute-CM.

Outpatient worsening heart failure in transthyretin amyloid cardiomyopathy: Findings from ATTRibute-CM.

Journal: European journal of heart failure
Published: March 26, 2026

Evaluation of the Current ATTR-CM Treatment Landscape via a Mathematical Model of TTR Dissociation and Amyloid Formation.

Evaluation of the Current ATTR-CM Treatment Landscape via a Mathematical Model of TTR Dissociation and Amyloid Formation.

Journal: CPT: pharmacometrics & systems pharmacology
Published: February 27, 2026

Affordability of Innovation -Cost-effectiveness and Budget Impact Analysis of Acoramidis in Transthyretin Amyloid Cardiomyopathy in the German Health-care System.

Affordability of Innovation -Cost-effectiveness and Budget Impact Analysis of Acoramidis in Transthyretin Amyloid Cardiomyopathy in the German Health-care System.

Journal: European heart journal. Quality of care & clinical outcomes
Published: February 20, 2026

Acoramidis in transthyretin amyloid cardiomyopathy: expanding evidence from ATTRibute-CM.

Acoramidis in transthyretin amyloid cardiomyopathy: expanding evidence from ATTRibute-CM.

Journal: Future cardiology
Published: February 09, 2026

Efficacy and Safety of Acoramidis in Japanese Adults With Symptomatic Transthyretin Amyloid Cardiomyopathy.

Efficacy and Safety of Acoramidis in Japanese Adults With Symptomatic Transthyretin Amyloid Cardiomyopathy.

Journal: Circulation reports
Published: January 26, 2026
Showing 1-12 of 93

Last Updated: 06/30/2026